Venomous snakes produce an array of toxic compounds, including procoagulants to defend themselves and incapacitate prey. The Australian snake Pseudonaja textilis has a venom-derived prothrombin activator homologous to coagulation factors V (FV) and Xa (FXa). Here we show that the FV component (pt-FV) has unique biological properties which subvert the normal regulatory restraints intended to restrict an unregulated procoagulant response. Unlike human-FV, recombinant pt-FV is constitutively active and does not require proteolytic processing to function. Sequence comparisons show that it has shed a large portion of the central B-domain including residues that stabilize the inactive procofactor state. Remarkably, pt-FV functions in the absence of anionic membranes as it binds snake-FXa with high affinity in solution. Furthermore, despite cleavage in the heavy chain, pt-FV is functionally resistant to the anticoagulant, activated protein C. We speculate this stability is due to noncovalent interactions and/or a unique disulfide bond in pt-FV linking the heavy and light chains. Taken together these findings provide a biochemical rationale for the strong procoagulant nature of venom prothrombinase.
INTRODUCTION
The circulation of blood coagulation factors as precursors and their localization to the site of vascular injury following activation are important factors which maintain normal hemostasis and restrict indiscriminate clotting. 1 Bypassing these regulatory paradigms can be life-threatening, yet organisms have evolved strategies that exploit these systems for a selective advantage. For example, the venom of numerous snake species comprises a diverse array of proteases which activate and overwhelm the host hemostatic system in an uncontrolled fashion. 2 Some of the most potent venoms come from the Australian elapid family including Pseudonaja textilis, Oxyuranus microlepidotus, and Oxyuranus scutellatus. 3 Their venom is considered the most toxic in the world and is unusual as it contains two coagulation proteins; factor V (FV) and a factor Xa (FXa)-like enzyme. [4] [5] [6] [7] [8] [9] [10] These proteins make up ~20-40% of the total venom and form a powerful procoagulant complex. 5, 7 This complex converts prothrombin to thrombin and its activity is enhanced, to varying degrees, by calcium and phospholipids, but not by the cofactor FVa. [4] [5] [6] [7] 11 Venom-derived FV from these snakes share ~44% homology with mammalian FV and have a similar domain structure (A1-A2-B-A3-C1-C2). 8, 10, 12 However, we were surprised to learn that their B-domains are remarkably short (~46 vs. ~800 residues in mammals) * . New genomic data show that while the length of the B-domain is variable and poorly conserved, especially in lower vertebrates (e.g. ~500 residues in 13, 14 ), a shortened version of this magnitude is unprecedented. In addition, the functional implications of a naturally occurring truncated B-domain are not understood. The generally accepted role of the B-domain is to somehow prevent or inhibit the constitutive activity of the precursor, FV.
Fugu rubripes
Conversion to the mature cofactor (FVa) involves proteolytic removal of the B-domain mediated by thrombin. 15 Once activated, FVa associates with FXa on an activated cellular surface in the presence of calcium ions to form prothrombinase, the physiological activator of prothrombin. 1, 15 More recently, using a series of human FV B-domain truncated variants, we found that discrete sequences within the B-domain * Amino acid numbering for pt-FV is as follows: the mature sequence starts at +1 and the remaining sequence is numbered consecutively to 1430.
The pt-FV B-domain is defined as the region removed following thrombin cleavage (residues 743-788).
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From contribute to the mechanism by which FV persists as an inactive procofactor. 16, 17 This suggests that the B-domain may play a direct role in keeping FV inactive in a sequence specific manner. These findings, combined with the unusual size of venom-derived FV raise the possibility that these snake species have shed regulatory components essential to keep FV inactive.
In the present study, we used recombinant venom-derived FV from the common brown snake, P.
textilis (pt-rFV; native protein from venom, pt-FV) to investigate the biological properties of this unique form of FV and to examine the mechanistic basis for the strong procoagulant nature of the venom-derived prothrombinase complex. Our work demonstrates that pt-rFV has been modified into a robust procoagulant acquiring multiple gain-of-function elements not present in mammalian FV. Unraveling the mechanistic and structural basis of these unique procoagulant properties will likely further our understanding of FV function. These findings also highlight how naturally occurring changes or adaptations can enhance the existing properties of a protein to presumably confer a selective advantage. Proteins. Human prothrombin was isolated from plasma as described previously. 19 Prethrombin-1 and prethrombin-2 were prepared and purified by established procedures, 20 and thrombin was obtained from
Haematologic Technologies. A constitutively active partial B-domainless form of human FV (hFV-810), rFVa, rFX and rFXa were prepared, purified and characterized as described. 16, 21 The purified enzymatic subunit of pseutarin C (pt-FXa) was a generous gift from QRxPharma (Sydney, Australia). Human activated protein C (APC) was obtained from Dr. Sriram Krishnaswamy (The Children's Hospital of Philadelphia). Molecular weights and extinction coefficients (E 0.1%, 280nm ) of the various proteins used are summarized as described. 16, 22 The molecular weight of pt-rFV was determined to be 170,000 and the extinction coefficient was assumed to be similar to rFV-810. For pt-FXa, values for the human protein were used. Unless otherwise noted, all functional assays were performed at 25°C in 20 mM Hepes, 0.15 M NaCl, 2 mM CaCl 2 , 0.1% polyethylene glycol 8000, pH 7.5 (assay buffer).
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From Analytical ultracentrifugation. Molecular weights were determined in a Beckman Optima XL-I analytical ultracentrifuge using interference optics. Sedimentation velocity was measured at 20°C in 20 mM Hepes, 150 mM NaCl, 5 mM CaCl 2 , pH 7.4 at 25,000 rpm with an AN60Ti rotor. Protein concentrations were: pt-rFV, 0.60 mg/mL (3.6 µM) and pt-FXa, 0.18 mg/mL (3.9 µM). For these experiments, pt-FXa was active site blocked with EGR-CH 2 Cl essentially as described. 23 Sedimentation coefficients and molecular weights were determined by g(s*) analysis.
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Construction of rFV variants. The P. textilis FV cDNA derived from the venom gland 10 was modified with flanking XmaI restriction sites and then subcloned into the pED expression plasmid. 16 The cDNA was further modified by exchanging sequences encoding the signal sequence of P. textilis FV with that of human FV using the technique of splicing by overlap extension. The final construct, pED-FV-ptex, encoded for the human FV signal peptide (residues -28 to -1) followed by the mature venom-derived pt- Expression and purification of pt-rFV. Plasmids encoding pt-FV or pt-FV-QQ were introduced into baby hamster kidney (BHK) cells and high producing stable clones were established as described. 16 Cells were expanded into triple flasks and cultured in DMEM/F12 media (no phenol red) supplemented with ITS and 2.5 mM CaCl 2 . Conditioned media was collected for 4-6 days, centrifuged, and stored at -20°C Protein characterization. Protein purity was assessed by SDS-PAGE using pre-cast 4-12% gradient gels (Invitrogen) under non-reducing and reducing conditions (50 mM dithiothreitol) employing the MOPS buffer system followed by staining with Coomassie Brilliant Blue R-250. N-terminal sequence analysis was performed in the laboratory of Dr. Alex Kurosky and Steve Smith at the University of Texas Medical Branch at Galveston or Dr. Jan Pohl, Center for Disease Control (Atlanta, GA). Chemical γ-carboxyglutamic acid (Gla) analysis on pt-FXa was carried out in our laboratory as described. 21 This analysis yielded 10.9 ± 0.34 mol Gla/mol protein out of 11 mol Gla/mol protein predicted from sequence alignments.
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Kinetics of protein substrate cleavage. Steady-state initial velocities of macromolecular substrate cleavage were determined discontinuously at 25°C as described. 21 The kinetic parameters of prothrombinase or FVa-FXa-catalyzed prothrombin or prethrombin-1 activation (K m and V max ) were legends) . For experiments in which pt-rFVa was used, pt-rFV (600 nM) was incubated with 2 nM thrombin at 37°C for 15 min followed by the addition of 2.4 nM hirudin.
APC inactivation of pt-rFV. The inactivation of the various cofactor proteins (500 nM; pt-rFV, ptrFVa, rhFVa, or h-FV-810) in the presence of PCPS (50 µM) was initiated by APC addition (10 nM or 750 nM). Aliquots of the reaction mixture were withdrawn at the indicated time intervals and assessed by SDS-PAGE (4-12 % gel) and through assessment of functional activity. In this assay, residual cofactor activity was assessed by measuring the effect of FVa on prothrombin activation essentially as described. For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
RESULTS
Expression and physical characterization of pt-rFV. The abundance of proteases in snake venom has precluded the isolation of a homogeneous uncleaved preparation of pt-FV. [4] [5] [6] [7] To circumvent this, we expressed and purified pt-rFV from BHK cells. Wild-type protein and a variant lacking both thrombin cleavage sites (pt-rFV-QQ; residues 742 and 788) migrated primarily as single bands (~160-180 kDa) on a reducing SDS-PAGE ( Figure 1, panel A) . Sedimentation velocity studies indicated that pt-rFV was homogeneous with a molecular weight of (170 ± 1) × 10 3 and a sedimentation coefficient (s 20, w ) of (8.30
± 0.01) × 10 -13 s (data not shown). While pt-rFV-QQ was not cleaved by thrombin, the wild-type protein was processed to pt-rFVa at the predicted sites ( Figure 1 ). 8, 10 FV purified from the crude venom of P. textilis and O. scutellatus has low activity in the presence of bovine FXa. 6, 7 Our results using human FXa and pt-rFV were consistent with these observations. The low activity appeared to be principally due to the finding that pt-rFV or thrombin-cleaved pt-rFV (ptrFVa) bound with a reduced affinity to membrane-bound human FXa (K d >400 nM) using established fluorescent binding measurements (data not shown). 16 To characterize pt-rFV, FXa purified from the venom of P. textilis (pt-FXa) was used in all subsequent experiments. SDS-PAGE analysis of pt-FXa is presented in Figure 1 along with N-terminal sequence analysis, which gave the expected results. The appearance of the light chain as a doublet is likely due to heterogeneous O-glycosylation.
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Pt-rFV is a constitutively active cofactor. Because of the strikingly short B-domain in pt-FV, we used a series of activity measurements to determine whether this domain functions to maintain the protein as a procofactor. As expected, pt-rFVa assembled with pt-FXa-membranes and rapidly activated prothrombin (Figure 2A ). Steady state kinetic constants with venom-derived prothrombinase were similar to those observed for human prothrombinase (Table 1) . 16, 22 Human FVa (data not shown) or a B-domain truncated derivative of FV, hFV-810, 16 also assembled with pt-FXa-membranes and activated prothrombin with comparable kinetic parameters ( Table 1) . In contrast to inactive human FV, 15 single chain pt-rFV or pt-rFV-QQ rapidly stimulated prothrombin activation and gave kinetic constants comparable to pt-rFVa ( Figure 2A and Table 1 ). Progress curves for either pt-rFV or pt-rFV-QQ increased linearly over time with no obvious lag in thrombin generation (data not shown). These data indicate that, unlike human FV, pt-FV is synthesized as a constitutively active cofactor and does not require proteolytic removal of the Bdomain to express procoagulant function.
Pt-rFV functions in the absence of anionic membranes. A central view of blood coagulation is that the interaction of coagulation proteins with negatively charged cellular surfaces is critical for normal hemostasis and has a substantial influence on reaction rates. 1 As expected, removal of anionic membranes from reaction mixtures containing hFV-810 or hFVa (data not shown) reduced the rate of prothrombin activation >150-fold ( Figure 2B ). No thrombin generation was observed under these conditions in the absence of the cofactor (data not shown). Surprisingly, initial rates of prothrombin activation using pt-rFV, pt-rFV-QQ, or pt-rFVa in the absence of membranes were reduced only ~10-fold compared to the enzyme in the presence of membranes ( Figure 2B and Table 1 ).
A difficulty in interpreting these data is that prothrombin binds membranes and thereby contributes to enhancing rates of thrombin generation. To address this, we measured the rate of prethrombin-1 activation in the presence and absence of membranes. Prethrombin-1 is a derivative of prothrombin lacking the membrane binding Gla and kringle-1 domains. 20 Consistent with results using prothrombin, the kinetics of prethrombin-1 activation using pt-rFV, pt-rFV-QQ, or pt-rFVa were similar to those using human prothrombinase ( Figure 3A and Table 1) . 22 Surprisingly however, removal of membranes from the reaction mixture had no appreciable effect on the rate of prethrombin-1 activation as the kinetic parameters for solution phase or pt-FXa-pt-rFV in the presence of membranes were equivalent ( Figure 3B and Table 1 ). These data indicate that the decreased rate of prothrombin activation with pt-FXa-pt-rFV was not due to decreased enzyme function, but rather to elimination of membrane binding by the substrate. Furthermore, these data show that the venom-derived enzyme complex, either in solution or in the presence of membranes, functions in an equivalent manner; a finding not mimicked with mammalian FXa-FVa.
Pt-FXa and pt-rFV form a high affinity complex. The data shown above suggest that pt-FXa was fully saturated with pt-rFV. To assess this directly, we used a functional binding measurement with prethrombin-2 as a substrate to infer the equilibrium dissociation constant for pt-FXa-pt-rFV in the presence or absence of membranes ( Table 2 ). As expected, in the presence of PCPS we found that the dissociation constant for cofactor binding to pt-FXa was ~ 3 nM regardless of the cofactor species, a value similar to the human proteins. 16 In marked contrast to the bovine system (K d for FXa-FVa in solution ~ 1-3 µM), the dissociation constant of pt-FXa for pt-rFV, pt-FV-QQ, or pt-rFVa increased only 2-3-fold in the absence of membranes (K d ~ 8 nM). 25, 26 Sedimentation velocity experiments showed that pt-rFV-pt-FXa formed a 1:1 stoichiometric complex in solution with a molecular weight of (213 ± 2) × 10 3 and a sedimentation coefficient (s 20, w ) of (9.33 ± 0.01) × 10 -13 s (data not shown). In contrast to the venom-derived cofactors, we were not able to reliably establish a binding constant for solution phase hFV-810-pt-FXa ( Table 2 ), suggesting that binding to soluble pt-FXa involves unique features on pt-rFV that are not present on hFV-810. Together these data indicate that the pt-FXa-pt-FV complex has bypassed the normal requirement for negatively charged membranes to form a high affinity 1:1 complex. 15 Sequence analysis of pt-FV indicates that these sites are not strictly conserved, suggesting it may be resistant to APC. 8 Using an APC concentration (10 nM) and reaction times (≤ 15 min) that resulted in the complete loss of hFVa or hFV-810 function, both pt-rFV and pt-rFVa retained full activity ( Figure 4A ), and SDS-PAGE analysis showed only limited cleavage of these proteins (data not shown). However, using higher concentrations of APC (750 nM), pt-FV was significantly proteolyzed over an extended time period ( Figure 4B, C) . N- . Surprisingly, despite proteolysis of pt-rFV, full procoagulant activity was retained ( Figure   4A , inset). Analysis of both reducing and non-reducing gels revealed that a large fraction of pt-rFV ( Figure 4B, C) is held together by one or more disulfide bonds between A2 C (either Cys 540 and/or Cys 642 ) and the light chain. This was also confirmed following treatment of pt-rFV with thrombin (data not shown). We speculate that noncovalent interactions along with this unique disulfide bond(s) may stabilize fragments generated by APC. Together these data show that despite APC cleavage at sites known to reduce cofactor activity, pt-rFV is functionally resistant to this anticoagulant.
Pt-rFV is functionally resistant to APC. APC is an important anticoagulant in the hemostatic

DISCUSSION
Most blood coagulation factors are synthesized as inactive precursors that only express activity following discrete proteolysis. The conformational changes that ensue allow these proteins to assemble on cellular surfaces localized at the site of vessel injury where they optimally function. 1 Furthermore, in most instances negative regulatory pathways are in place to limit their activity. Here we show that venom FV from P. textilis circumvents these paradigms of normal hemostasis through a variety of changes transforming it into a potent procoagulant. These procoagulant enhancements likely provide this snake with a selective advantage by facilitating massive disseminated coagulation following envenomation of prey. 3, 28 Our data support the conclusion that pt-FV is synthesized in an active state and, unlike human FV, does not require proteolytic removal of the B-domain to express procoagulant activity. This represents the first reported example of a constitutively procoagulant form of FV in nature. Based on our prior studies with human FV, we speculate that the molecular basis for this finding is principally related to the short B-domain of pt-FV. The FV B-domain is an unusual domain with no known homology to any other protein including the B-domain of the homologous clotting factor, FVIII. In most vertebrates, it corresponds to >40% of the mass of the protein, has a relatively low sequence homology, and displays a peculiar heavily glycosylated structure with numerous short tandem repeats of unknown function. 29 Despite this lack of conservation, one of its roles is to inhibit constitutive cofactor activity as it is well established that proteolytic removal of the B-domain activates FV. microlepidotus lack this conserved sequence. 8, 10 We speculate that the absence of this basic region, and possibly other structural features, switches the functional state of pt-FV from an inactive procofactor to a constitutively active cofactor. Thus pt-FV represents a clear biological correlate to structure/function studies with human FV and is a naturally occurring example of a protein that has acquired a new functional state through loss of inhibitory sequences. Despite this loss, pt-FV has retained two out of three thrombin cleavage sites flanking the heavy and light chains (Arg 742 and Arg 788 ). While our work
shows that cleavage at these sites is without functional consequence, their retention raises the possibility that they may have some important in vivo biological function yet to be fully appreciated. Another possibility is that there simply was no selective pressure to change them. Other than perhaps stabilizing the molecule, there would appear to be no real advantage in eliminating these sites, thereby making the molecule resistant to thrombin.
A key underlying feature in any hemostatic response is that the assembly of coagulation proteins is localized to damaged vascular and peripheral blood cells at the site of injury. 1 This promotes enzyme complex assembly and contributes to a profound enhancement in reaction rate. 1 Work detailed here
shows that pt-FV has bypassed these requisite restraints as it binds pt-FXa with high affinity in solution and functions equivalently to the membrane-bound complex. From the standpoint of evolving a strong procoagulant as a biological weapon, bypassing the membrane binding step promotes a disseminated rather than a localized response following envenomation. However, the molecular basis for these findings is not clear. In the mammalian system, FXa and FVa have a micromolar affinity in solution while the introduction of anionic membranes reduces the affinity to the nanomolar range. 1, 25, 26 It is generally believed that the membrane surface promotes the assembly of FXa and FVa in at least two possible ways. 1 The increased affinity upon membrane binding could be due to the reduction in the degrees of freedom for protein reorientation once bound to a membrane surface. This reduction of dimensionality would then increase the frequency of productive collisions. Alternatively, the binding of FVa or FXa to a membrane surface could cause a conformational change in either of these proteins that fundamentally As a further procoagulant enhancement, pt-FV is functionally resistant to APC despite cleavage in the heavy chain at Lys 507 and Arg 742 . We speculate that non-covalent interactions contribute to this stabilization as it has been previously shown in the bovine system that a portion of the A2 domain remains associated following cleavage at Arg 506 . 35 Our data are consistent with this as they indicate that cleavage at the Arg 506 equivalent site in pt-FV has no obvious deleterious effect on cofactor function. following analysis of all data sets to a rectangular hyperbola, and the fitted kinetic constants can be found in Table 2 . The data are representative of two similar experiments. For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
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